TREACE MEDICAL CONCEPTS, INC. (TMCI)
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Treace Medical Concepts, Inc.
No splits on record
Nothing in TMCI's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $212.69M | $209.36M | $187.12M | $141.84M | $94.42M | $57.37M | $39.42M |
| YoY Growth | 1.6% | 11.9% | 31.9% | 50.2% | 64.6% | 45.5% | - |
| Cost of Revenue | $42.94M | $41.09M | $35.18M | $27.52M | $16.89M | $12.47M | $7.63M |
| Gross Profit | $169.75M | $168.26M | $151.94M | $114.31M | $77.53M | $44.9M | $31.79M |
| Gross Margin | 79.8% | 80.4% | 81.2% | 80.6% | 82.1% | 78.3% | 80.6% |
| Research and Development | $20.28M | $20.59M | $15.44M | $13.58M | $10.2M | $5.85M | $5.07M |
| Selling, General, and Administrative | $203.62M | $203.36M | $187.93M | $137.57M | $83.84M | $38.19M | $30.25M |
| Other | $0 | $0 | $0 | -$1.99M | $0 | $0 | $0 |
| Total Operating Expenses | $223.91M | $223.95M | $203.37M | $149.16M | $94.04M | $44.04M | $35.32M |
| Operating Income (EBIT) | -$54.15M | -$55.69M | -$51.43M | -$34.84M | -$16.51M | $855K | -$3.54M |
| Operating Margin | -25.5% | -26.6% | -27.5% | -24.6% | -17.5% | 1.5% | -9.0% |
| Interest Expense | $5.32M | $5.26M | $5.17M | $4.4M | $4.06M | $4.52M | $841K |
| Interest Income | $2.78M | $4.88M | $6.73M | $1.31M | $18K | $0 | $111K |
| Other Income (Expense) | -$4.85M | -$55K | $1.9M | -$7.97M | -$4.04M | -$4.52M | -$730K |
| Income Before Tax (EBT) | -$59M | -$55.74M | -$49.53M | -$42.81M | -$20.55M | -$3.67M | -$4.26M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$59M | -$55.74M | -$49.53M | -$42.81M | -$20.55M | -$3.67M | -$4.26M |
| Net Income Margin | -27.7% | -26.6% | -26.5% | -30.2% | -21.8% | -6.4% | -10.8% |
| Supplementary Data | |||||||
| EPS | -0.93 | -0.90 | -0.81 | -0.77 | -0.38 | -0.08 | -0.10 |
| Diluted EPS | -0.93 | -0.90 | -0.81 | -0.77 | -0.38 | -0.08 | -0.10 |
| Weighted Average OS | 63.27M | 62.11M | 60.85M | 55.28M | 54.18M | 51.17M | 51.17M |
| EBITDA | -$43.18M | -$42.07M | -$39.01M | -$36.28M | -$15.81M | $2.06M | -$2.63M |
| EBITDA Margin | -20.3% | -20.1% | -20.8% | -25.6% | -16.7% | 3.6% | -6.7% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $10.71M | $11.35M | $12.98M | $19.47M | $105.83M | $18.08M | $12.14M |
| Short-Term Investments | $37.66M | $64.33M | $110.22M | $61.78M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $48.37M | $75.68M | $123.2M | $81.25M | $105.83M | $18.08M | $12.14M |
| Accounts Receivable | $42.16M | $40.8M | $38.06M | $29.2M | $18.57M | $14.49M | $10.41M |
| Inventory | $36.03M | $39.26M | $29.25M | $19.33M | $10.56M | $7.82M | $5.56M |
| Other Current Assets | $5.5M | $5.67M | $7.85M | $3.62M | $0 | $0 | $0 |
| Total Current Assets | $132.05M | $161.4M | $198.36M | $133.4M | $137.97M | $40.98M | $28.57M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $37.37M | $34.4M | $31.56M | $25.48M | $2.85M | $829K | $1.15M |
| Goodwill | $12.81M | $12.81M | $12.81M | $0 | $0 | $0 | $0 |
| Intangible Assets | $7.13M | $8.07M | $9.03M | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.22M | $407K | $146K | $146K | $0 | $0 | $0 |
| Total Long-Term Assets | $58.53M | $55.69M | $53.55M | $25.62M | $2.85M | $829K | $1.15M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $190.58M | $217.09M | $251.91M | $159.02M | $140.82M | $41.81M | $29.72M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $6.73M | $10.52M | $11.84M | $8.67M | $4.06M | $2.27M | $931K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $1.79M | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $23.91M | $2.22M | $24.25M | $7.67M | $4.46M | $1K | $0 |
| Total Current Liabilities | $30.64M | $34.92M | $45.03M | $30.25M | $18.21M | $11.6M | $7.33M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $13.98M | $53.31M | $53.01M | $52.71M | $29.36M | $29.19M | $19.22M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $58.63M | $37K | $37K | $0 | $173K | $244K | $0 |
| Total Long-Term Liabilities | $72.61M | $69.28M | $68.94M | $68.25M | $29.54M | $29.43M | $19.22M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $103.25M | $104.2M | $113.97M | $98.5M | $47.75M | $41.03M | $26.55M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $7.93M | $7.93M |
| Common Stock | $64K | $62K | $62K | $55K | $45K | $28K | $28K |
| Retained Earnings | -$248.99M | -$189.99M | -$134.25M | -$84.72M | -$41.91M | -$21.35M | -$17.69M |
| Comprehensive Income & Other | $72K | $97K | $163K | -$27K | $0 | $0 | $0 |
| Other Stockholders' Equity | $336.26M | $302.82M | $272.12M | $145.19M | $134.93M | $22.1M | $20.82M |
| Total Equity | $87.33M | $112.89M | $137.94M | $60.53M | $93.07M | $776K | $3.16M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $190.58M | $217.09M | $251.91M | $159.02M | $140.82M | $41.81M | $29.72M |
| Supplementary Data | |||||||
| Total Debt | $13.98M | $69.65M | $70.3M | $68.59M | $29.36M | $30.98M | $19.22M |
| Net Debt | $3.27M | $58.3M | $57.32M | $49.12M | -$76.47M | $12.9M | $7.08M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$59M | -$55.74M | -$49.53M | -$42.81M | -$20.55M | -$3.67M | -$4.26M |
| Depreciation & Amortization | $10.5M | $8.42M | $5.35M | $2.13M | $685K | $1.21M | $793K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $419K | $2.14M | $0 |
| Stock-Based Compensation | $33.82M | $30.6M | $17.35M | $8.11M | $3.41M | $919K | $815K |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$2.09M | -$5.69M | -$9.3M | -$11.04M | -$4.23M | -$4.29M | -$6.02M |
| Inventory | $3.22M | -$10.01M | -$9.85M | -$8.77M | -$3.09M | -$3.4M | -$2.81M |
| Accounts Payable | -$3.8M | -$1.31M | $3.17M | $4.61M | $1.79M | $1.33M | -$236K |
| Other Working Capital | -$5.92M | -$8.42M | $6.24M | $9.39M | $4.19M | $1.04M | $3.76M |
| Total Working Capital Change | -$8.58M | -$25.43M | -$9.74M | -$5.81M | -$1.33M | -$5.32M | -$5.31M |
| Other Non-Cash Items | $7.29M | $4.99M | $1.99M | $7.73M | $176K | $221K | $292K |
| Net Cash from Operating | -$15.97M | -$37.17M | -$34.58M | -$30.65M | -$17.19M | -$4.49M | -$7.67M |
| Investing Activities | |||||||
| Capital Expenditures | -$13.52M | -$11.59M | -$11.46M | -$14.84M | -$2.71M | -$1.07M | -$1.21M |
| Acquisitions | $0 | $0 | -$20M | $61.68M | $0 | $0 | $0 |
| Purchases of Investments | -$40.57M | -$71.58M | -$169.87M | -$63.41M | $0 | $0 | $0 |
| Sales of Investments | $67.34M | $118.55M | $120.02M | $1.73M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$61.68M | $0 | $0 | $0 |
| Net Cash from Investing | $13.25M | $35.38M | -$81.3M | -$76.52M | -$2.71M | -$1.07M | -$1.21M |
| Financing Activities | |||||||
| Debt Repaid | -$1.8M | - | - | -$19.61M | $1.79M | -$11.32M | -$20M |
| Common Stock Issuance | $546K | $428K | $109.4M | $2.19M | $109.44M | $364K | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$902K | -$268K | -$13K | -$989K | $0 | -$179K | -$261K |
| Net Cash from Financing | $2.08M | $160K | $109.38M | $20.81M | $107.65M | $11.5M | $19.74M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$642K | -$1.63M | -$6.49M | -$86.36M | $87.75M | $5.94M | $10.86M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$15.97M | -$37.17M | -$34.58M | -$30.65M | -$17.19M | -$4.49M | -$7.67M |
| Capital Expenditure | -$13.52M | -$11.59M | -$11.46M | -$14.84M | -$2.71M | -$1.07M | -$1.21M |
| Free Cash Flow | -$29.49M | -$48.76M | -$46.03M | -$45.49M | -$19.9M | -$5.56M | -$8.88M |
| Cash at Beginning | $11.35M | $12.98M | $19.47M | $105.83M | $18.08M | $12.14M | $1.28M |
| Cash at End | $10.71M | $11.35M | $12.98M | $19.47M | $105.83M | $18.08M | $12.14M |